Intelligence · Patents
Patents expiring in 2042
Annual patent cliff calendar for 2042 — US pharmaceutical patents by expiration date.
- Patents
- 1,738
Quick answer
1,738 indexed pharmaceutical patents have expiration dates in 2042. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11260120
Immunogenic composition comprising a fusion peptide derived from superantigen toxoids
granted -
US 11260070
Methods of treating feline coronavirus infections
granted -
US 11260089
Products of manufacture comprising bacteriophages
granted -
US 11261164
Small molecule agonists of neurotensin receptor 1
granted -
US 11260073
Compounds and methods for modulating C90RF72
granted -
US 11261152
Inhibitors of the N-terminal domain of the androgen receptor
granted -
US 11261151
Methods for making and using endoxifen
granted -
US 11261188
Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
granted -
US 11261190
Dihydropyrimidine compounds and uses thereof in medicine
granted -
US 2022062444
PHARMACEUTICAL COMPOSITIONS COMPRISING GD-COMPLEXES AND POLYARYLENE ADDITIVES
granted -
WO 2022043557
MÉTHODE DE TRAITEMENT DE CANCERS EXPRIMANT LE PSMA
granted -
WO 2022043558
MÉTHODE DE TRAITEMENT DE CANCERS EXPRIMANT LE PSMA
granted -
US 11266641
Formulations of a somatostatin modulator
granted -
US 11266655
Methods and compositions for treating urea cycle disorders
granted -
US 11266657
Pharmaceutical compositions comprising meloxicam
granted -
US 11266611
More potent and less toxic formulations of epinephrine and methods of medical use
granted -
US 11267782
Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2α inhibitors
granted -
US 11266661
Vaginal inserted estradiol pharmaceutical compositions and methods
granted -
US 11267785
Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
granted -
US 11267822
BET bromodomain protein degraders with cleavable linkers
granted -
US 11266488
Tissue repair fiber membrane, preparation method and application thereof, and tissue repair product
granted -
US 11266746
Therapeutic antitumor combination of a TLR4 ligand with other treatments
granted -
US 11266676
MicroRNA in T cell activation
granted -
US 11266693
Nucleic acids encoding engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene
granted -
US 11267859
GM-CSF mimetics and methods of making and using same
granted -
US 11266742
Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
granted -
US 11267812
KRAS G12C inhibitors
granted -
US 11266720
Factor VIII-FC chimeric and hybrid polypeptides, and methods of use thereof
granted -
US 11267845
Inhibitors of CD73-mediated immunosuppression
granted -
US 11267896
Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof
granted -
US 11268065
Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
granted -
US 11268096
Compounds for modulating Fc-epsilon-RI-beta expression and uses thereof
granted -
US 11268098
Non-aggregating immunostimulatory oligonucleotides
granted -
US 11266699
Synergistic bacterial compositions and methods of production and use thereof
granted -
US 11266622
Method of treatment
granted -
US 11268154
Methods for the identification, evaluation and treatment of patients having multiple myeloma
granted -
US 11268077
Materials and methods for treatment of hemoglobinopathies
granted -
US 11267893
Anti-IL36R antibodies
granted -
US 11267832
Mn(II)-based sensors to detect zinc in vivo with MRI
granted -
US 11266726
Compositions and methods for the treatment of HER2-expressing solid tumors
granted -
US 11266694
Restimulation of cryopreserved tumor infiltrating lymphocytes
granted -
US 11266692
Intracellular genomic transplant and methods of therapy
granted -
US 11266649
Pharmaceutical formulations
granted -
US 11266724
Modified factor VII polypeptides for subcutaneous administration and on-demand treatment
granted -
US 11268145
Methods for treating Cushing's syndrome
granted -
EP 3964220
PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR BEHANDLUNG VON OSTEOPOROSE
granted -
US 2022072166
METHOD OF TREATMENT OF NEUROENDOCRINE TUMORS
granted -
US 11274123
1,2,4-oxadiazole compounds as inhibitors of CD47 signalling
granted
Frequently asked questions
How many pharma patents expire in 2042?
1,738 published patents in our USPTO index have expiration dates falling in calendar year 2042.